Novo Nordisk, a global pharmaceutical company, has announced a reduction in the prices of its weight-loss medications, Wegovy and Ozempic. These adjustments will result in a monthly cost of $349 for eligible patients. The decision follows discussions with Eli Lilly regarding streamlined access to the medications within the United States. The company cited increased demand and market dynamics as contributing factors to the pricing changes. These reductions are part of a broader strategy to expand patient accessibility and market share.
Credits: US Top News and Analysis
